$0.82
3.61%
Downside
Day's Volatility :4.19%
Upside
0.61%
34.15%
Downside
52 Weeks Volatility :73.66%
Upside
60.0%
Period | Seres Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -34.94% | -2.8% | 0.0% |
6 Months | -24.09% | 4.5% | 0.0% |
1 Year | -43.07% | 17.7% | 0.0% |
3 Years | -87.27% | 9.9% | -25.0% |
Market Capitalization | 133.2M |
Book Value | -$0.57 |
Earnings Per Share (EPS) | -1.19 |
PEG Ratio | -0.11 |
Wall Street Target Price | 3.89 |
Profit Margin | 0.0% |
Operating Margin TTM | -42211.23% |
Return On Assets TTM | -27.1% |
Return On Equity TTM | -538.57% |
Revenue TTM | 374.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -93.4% |
Gross Profit TTM | -165.8M |
EBITDA | -151.6M |
Diluted Eps TTM | -1.19 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.94 |
EPS Estimate Next Year | -0.55 |
EPS Estimate Current Quarter | -0.27 |
EPS Estimate Next Quarter | -0.26 |
What analysts predicted
Upside of 374.39%
Sell
Neutral
Buy
Seres Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Seres Therapeutics Inc | -14.72% | -24.09% | -43.07% | -87.27% | -77.78% |
Regeneron Pharmaceuticals, Inc. | -19.94% | -7.23% | 5.93% | 31.14% | 169.97% |
Biontech Se | -5.69% | 25.74% | 21.03% | -58.77% | 584.62% |
Alnylam Pharmaceuticals, Inc. | -3.43% | 77.77% | 69.8% | 60.25% | 192.92% |
Vertex Pharmaceuticals Incorporated | 1.32% | 18.36% | 28.88% | 156.73% | 136.88% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Seres Therapeutics Inc | NA | NA | -0.11 | -0.94 | -5.39 | -0.27 | NA | -0.57 |
Regeneron Pharmaceuticals, Inc. | 24.57 | 24.57 | 1.27 | 44.77 | 0.17 | 0.08 | NA | 261.41 |
Biontech Se | 160.8 | NA | 0.04 | -2.76 | -0.03 | -0.02 | NA | 80.22 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.39 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.16 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Seres Therapeutics Inc | Buy | $133.2M | -77.78% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $102.2B | 169.97% | 24.57 | 32.04% |
Biontech Se | Buy | $27.1B | 584.62% | 160.8 | -18.75% |
Alnylam Pharmaceuticals, Inc. | Buy | $36.5B | 192.92% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $122.6B | 136.88% | 32.84 | -4.74% |
Insights on Seres Therapeutics Inc
Revenue is down for the last 3 quarters, 126.47M → 64.0K (in $), with an average decrease of 89.6% per quarter
Netprofit is up for the last 4 quarters, -47.85M → -32.86M (in $), with an average increase of 13.6% per quarter
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.8% return, outperforming this stock by 112.9%
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 60.2% return, outperforming this stock by 147.5%
Flagship Ventures Management, Inc.
FMR Inc
Vanguard Group Inc
TANG CAPITAL MANAGEMENT LLC
Millennium Management LLC
BlackRock Inc
seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.
Organization | Seres Therapeutics Inc |
Employees | 233 |
CEO | Mr. Eric D. Shaff M.B.A. |
Industry | Health Technology |
Victoryshares International
$0.82
+0.26%
Clearbridge Focus Value Esg Etf
$0.82
+0.26%
Citizens & Northern Corp
$0.82
+0.26%
Angel Oak Financ Strat Inc
$0.82
+0.26%
Pgim Jennison Focused Growth Etf
$0.82
+0.26%
Israel Acquisitions Corp
$0.82
+0.26%
Foremost Lithium Resource & Technology Ltd
$0.82
+0.26%
Blackrock Etf Trust Long Term Us Eqt
$0.82
+0.26%
Overlay Shares Shrt Term Bon
$0.82
+0.26%